Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
In Vitro Immunomodulation in Membranous Nephropathy Relapses (BIOGEM)

In order to propose the best therapeutic option to relapsed MN patients with strong activation of the Th17 pathway, the investigators propose to study in vitro the effect of different immunomodulators on the Th17/Treg balance, assessed by cytokine profile and lymphocyte phenotyping using flow cytometry.

nephropathy
remission
proteinuria
  • 0 views
  • 11 Jul, 2022
  • 1 location
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis

Psoriasis has been associated with an increasing risk for atherosclerosis. The investigators investigated whether surrogate markers of subclinical atherosclerosis, vascular dysfunction and myocardial dysfunction are impaired in patients with psoriasis compared to normal controls ,coronary artery disease patients and untreated hypertension subjects. The investigators also examined the effect of treatment …

secukinumab
atherosclerosis
apremilast
Accepts healthy volunteers
cyclosporine
  • 0 views
  • 18 Apr, 2022
  • 1 location
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China (UNMASK2)

This non-interventional, prospective, multi-center study aims to provide short- and longterm treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to

secukinumab
plaque psoriasis
  • 0 views
  • 24 Oct, 2022
  • 30 locations
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

This is a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for up to 52 weeks.

  • 0 views
  • 07 Oct, 2022
  • 1 location
2 Years Prospective Study to Collect Real-life Data On the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial spondyloarthriTis (PROMPT) (PROMPT)

This is an observational, prospective primary data collection study. The duration of observation is 2 years after study enrolment date. Disease and treatment history will be retrospectively reviewed from medical record at enrollment with no time limits for the key diagnosis of enrolment (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and …

secukinumab
spondylitis
plaque psoriasis
arthritis
psoriasis
  • 0 views
  • 23 Oct, 2022
  • 4 locations